Cloning expeditions: risky but rewarding.
In the 1980s, a good part of my laboratory was using the then-new recombinant DNA techniques to clone and characterize many important cell surface membrane proteins: GLUT1 (the red cell glucose transporter) and then GLUT2 and GLUT4, the red cell anion exchange protein (Band 3), asialoglycoprotein receptor subunits, sucrase-isomaltase, the erythropoietin receptor, and two of the subunits of the transforming growth factor β (TGF-β) receptor. These cloned genes opened many new fields of basic research, including membrane insertion and trafficking of transmembrane proteins, signal transduction by many members of the cytokine and TGF-β families of receptors, and the cellular physiology of glucose and anion transport. They also led to many insights into the molecular biology of several cancers, hematopoietic disorders, and diabetes. This work was done by an exceptional group of postdocs and students who took exceptionally large risks in developing and using novel cloning technologies. Unsurprisingly, all have gone on to become leaders in the fields of molecular cell biology and molecular medicine.
Whitehead Institute for Biomedical Research, Departments of Biology and Biological Engineering, MIT, Cambridge, Massachusetts, USA.
Harvey
H
Lodish
D000818:Animals; D003001:Cloning, Molecular; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D008404:Massachusetts; D008565:Membrane Proteins / Q000096:biosynthesis / Q000235:genetics; D008967:Molecular Biology / Q000266:history
D008565:Membrane Proteins